Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study.

Wannez, Adeline;Devalet, Bérangère;Bouvy, Céline;Laloy, Julie;Mullier, François;et.al.
(2017) Thrombosis Research : vascular obstruction, hemorrhage and hemostasis — Vol. 156, p. 142-148 (2017)

Files

WannezAThrombRes2017.pdf
  • Restricted Access
  • Adobe PDF
  • 963.47 KB
Request a copy

Details

Authors
  • Wannez, AdelineUNamur
    Author
  • Devalet, BérangèreUCLouvain
    Author
  • Bouvy, CélineUNamur
    Author
  • Laloy, JulieUNamur
    Author
  • Chatelain, BernardUCLouvain
    Author
  • Chatelain, ChristianUCLouvain
    Author
  • Mullier, FrançoisUCLouvain
    Author
Show more
Abstract
(en) INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a disease characterized by the susceptibility of blood cells to attack by the complement system, inducing extracellular vesicle (EV) production. Thromboembolism is the leading cause of death in this condition. Eculizumab, a humanized monoclonal antibody which inhibits the C5 protein of the complement, reduces the thrombotic risk in PNH. MATERIALS AND METHOD: We conducted a pilot, prospective, open-label, longitudinal clinical study with six PNH patients treated with eculizumab. The aim was to measure, by flow cytometry, the EVs' production in the patients' platelet-free plasma (PFP) before and during the treatment. We also assessed the procoagulant activity in PFP using STA®-Procoag-PPL and thrombin generation assays (TGA). A high-sensitive version of TGA was also used to study the procoagulant profile induced by the EVs using EVs pelleted from PFP. RESULTS: We observed a decrease in platelet EV count with eculizumab treatment (p<0.05). STA®-Procoag-PPL assay showed a decrease of the procoagulant profile induced by procoagulant phospholipids (PL) during treatment. These results were not confirmed by TGA on PFP, due to a lack of sensitivity. Thus, we used a high-sensitive version of TGA that enabled us to observe variation in the procoagulant profile induced by the EVs with eculizumab (p<0.05). CONCLUSIONS: Eculizumab has an impact on the extent of EV production and on the procoagulant profile induced by the procoagulant PL and the EVs. One factor in the antithrombotic action of eculizumab is its ability to decrease EV production and the procoagulant profile induced by PL and EVs.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Wannez, A., Devalet, B., Bouvy, C., Laloy, J., Bihin, B., Chatelain, B., Chatelain, C., Dogné, J.-M., & Mullier, F. (2017). Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study. Thrombosis Research : vascular obstruction, hemorrhage and hemostasis, 156, 142-148. https://doi.org/10.1016/j.thromres.2017.06.013 (Original work published 2017)